OmniAb, Inc. OABI
Set alert
At close
Pre-market · Nov 3, 4:00 AM ET
- YTD
- +175.14%
- 1 year
- +228.39%
- Open
- 5.11
- Prev close
- 5.11
- Mkt cap
- 742.43M
- Vol
- 2.15M
- Avg vol
- 1.71M
- EPS
- -0.34
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 4.94
- High
- 5.31
- Forward P/E
- -8.95
- Beta
- 0.44
- Short ratio
- 14.24
- Inst. own
- 68.95%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 8, 2024
- 50-d avg
- 4.00
- 200-d avg
- 4.38
- 1y target
- 9.63
5D chart
Signals (82)
| Name | Time | Ago |
|---|---|---|
| RSI: Overbought | Oct 30, 3:55 PM | 3 days ago |
| SMA: Bullish | Oct 30, 3:40 PM | 3 days ago |
| SMA: Bearish | Oct 30, 3:35 PM | 3 days ago |
| SMA: Bullish | Oct 30, 2:55 PM | 3 days ago |
| MACD: Buy Signal | Oct 30, 2:45 PM | 3 days ago |
| MACD: Sell Signal | Oct 30, 2:40 PM | 3 days ago |
| MACD: Buy Signal | Oct 30, 2:35 PM | 3 days ago |
| SMA: Bullish | Oct 30, 2:20 PM | 3 days ago |
| SMA: Bearish | Oct 30, 1:40 PM | 3 days ago |
| MACD: Sell Signal | Oct 30, 1:40 PM | 3 days ago |
| SMA: Bullish | Oct 30, 1:15 PM | 3 days ago |
| SMA: Bearish | Oct 30, 12:05 PM | 3 days ago |
| SMA: Bullish | Oct 30, 11:45 AM | 3 days ago |
| SMA: Bearish | Oct 30, 11:40 AM | 3 days ago |
| SMA: Bullish | Oct 30, 11:15 AM | 3 days ago |
| MACD: Buy Signal | Oct 30, 10:35 AM | 3 days ago |
| SMA: Bullish | Oct 30, 10:25 AM | 3 days ago |
| RSI: Oversold | Oct 30, 10:05 AM | 3 days ago |
| RSI: Oversold | Oct 30, 9:45 AM | 3 days ago |
| SMA: Bearish | Oct 30, 9:30 AM | 3 days ago |
Newest 20 of 82.
News
2 days ago seekingalpha.com
OmniAb: A Self-Funding Option Book On 433 Partner Programs
OmniAb has reached self-sustaining cash flow, no longer requiring investor funding to operate, with 2026 projected as break-even for net cash usage. OABI's portfolio model offers contractually…
3 days ago benzinga.com
OmniAb Q3 2026 Earnings Call Transcript
OmniAb (NASDAQ:OABI) reported third-quarter financial results on Friday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by…
3 days ago seekingalpha.com
OmniAb, Inc. (OABI) Q3 2026 Earnings Call Transcript
OmniAb, Inc. (OABI) Q3 2026 Earnings Call Transcript
3 days ago marketbeat.com
OmniAb Q3 Earnings Call Highlights
OmniAb NASDAQ: OABI reported higher third-quarter revenue and raised its full-year 2026 revenue and year-end cash outlook, citing partner-program milestones, expanding service revenue and early…
3 days ago zacks.com
OmniAb, Inc. (OABI) Reports Q3 Loss, Tops Revenue Estimates
OmniAb, Inc. (OABI) came out with a quarterly loss of $0.12 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.14 per share a year ago.
3 days ago benzinga.com
12 Health Care Stocks Moving In Friday's Pre-Market Session
Gainers NRX Pharmaceuticals (NASDAQ:NRXP) shares increased by 12.0% to $2.98 during Friday's pre-market session. The market value of their outstanding shares is at $115.1 million. Intensity…
-
3 days ago benzinga.com
OmniAb Q3 EPS $(0.12), Inline, Sales $3.993M Beat $3.492M Estimate
OmniAb (NASDAQ:OABI) reported quarterly losses of $(0.12) per share which met the analyst consensus estimate. This is a 14.29 percent increase over losses of $(0.14) per share from the same period…
-
3 days ago benzinga.com
OmniAb Raises FY2026 Sales Guidance from $32.000M-$36.000M to $35.000M-$39.000M vs $35.036M Est
OmniAb (NASDAQ:OABI) raises FY2026 sales outlook from $32.000 million-$36.000 million to $35.000 million-$39.000 million vs $35.036 million estimate.
3 days ago businesswire.com
OmniAb Reports Third Quarter 2026 Financial Results and Business Highlights
EMERYVILLE, Calif.--(BUSINESS WIRE)---- $OABI #OABI--OmniAb, Inc. (NASDAQ: OABI), a provider of cutting-edge discovery research technology to enable the discovery of next-generation therapeutics,…
-
3 weeks ago benzinga.com
Leerink Partners Maintains Outperform on OmniAb, Raises Price Target to $12
Leerink Partners analyst Puneet Souda maintains OmniAb (NASDAQ:OABI) with a Outperform and raises the price target from $10 to $12.
-
3 weeks ago benzinga.com
StoneX Maintains Buy on OmniAb, Raises Price Target to $6
StoneX analyst Robert Wasserman maintains OmniAb (NASDAQ:OABI) with a Buy and raises the price target from $4 to $6.